A Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT
1. Stage I-IV breast cancer. Patients must have clinical or
radiographic evidence of localized or metastatic disease.
2. Criteria for NIS-positivity are defined as: >= 20% of cells with plasma membrane
and/or strong intracellular/plasma membrane immunoreactivity 3. Any previous therapy
including radiation therapy is allowable. 4. Women 18 years of age or older. 5. Patients
must have a life expectancy of at least 3 months 6. Patients with ECOG Performance Status
0-3 will be eligible. 7. If on chemotherapy, thyroid suppression should be initiated no
sooner than two weeks after last chemotherapy cycle.
8. Ability to understand and willingness to sign a written informed consent document.
9. Discontinuation of hormonal or biological therapies for the 10 days of the study is
preferred but not mandated.
10. Laboratory tests (CBC, comprehensive metabolic panel) must be performed within 120 day
prior to study initiation.
Exclusion Criteria:1. History of metastatic thyroid cancer 2. Exclude the use of
cytotoxic, hormonal or biological agents for one week prior to and during imaging.
3. Pregnant or nursing patients will be excluded from the study as iodide can accumulate
in the breast and is transported across the placenta.
4. Inability to tolerate thyroid hormone and/or methimazole pre-imaging treatment.
5. History of thyroid cancer (because patient could have concomitant thyroid cancer
metastases and therefore competitively concentrate radioiodides) 6. Psychiatric or
addictive disorders that are not adequately controlled and would preclude obtaining
7. Patients with heart disease or other significant cardiac risk factors will be excluded
from receiving thyroid suppressive therapy so as to avoid precipitating a cardiac